---
schema_version: "secwatch.filing_event.v1"
accession: "0001829126-23-004890"
form_type: "8-K"
ticker: "ZEOX"
cik: "0001557376"
company_name: "Zeo ScientifiX, Inc."
filed_at: "2023-07-26T23:59:59+00:00"
generated_at: "2026-06-13T02:19:37.727341+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Organicell reports no safety events in Phase 1/2a studies of Zofin; plans Phase 2 in 2024

## Summary
- No therapy-related safety events or significant adverse events across three Phase 1/2a studies with over 20 Zofin-treated patients.
- Studies include knee osteoarthritis, moderate-to-severe COVID-19, and long-haul COVID-19 (expected completion October 2023).
- Company plans to initiate larger Phase 2 studies for multiple chronic conditions in 2024.

## SEC filing metadata
- accession: 0001829126-23-004890
- form_type: 8-K
- ticker: ZEOX
- cik: 0001557376
- company_name: Zeo ScientifiX, Inc.
- filed_at: 2023-07-26T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1557376/000182912623004890/0001829126-23-004890-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1557376/000182912623004890/organicellregen_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001829126-23-004890
- JSON: https://secwatch.observer/filing/0001829126-23-004890.json
- Plain text: https://secwatch.observer/filing/0001829126-23-004890.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.